Pain Therapeutics (PTIE) - Bear of the Day
Pain Therapeutics, Inc. is focused on the development of novel treatments for the management of pain and other therapeutic indications. Lead pipeline candidate, Remoxy, an abuse-deterrent version of pain drug oxycodone, should have significant commercial opportunity upon approval due to its ability to reduce the potential of drug abuse / misuse.
While we believe that Remoxy will see significant demand once launched, we are concerned that the candidate may not receive final approval at the upcoming FDA action date of December 10, 2008. Remoxy received a mixed response from an FDA advisory panel recently; we fear that the FDA might require the company to conduct additional studies to establish its abuse-deterrent qualities.
We are also concerned about the possibility of the company facing a patent infringement lawsuit for Remoxy. Moreover, the rest of the company's pipeline is too early stage to get excited about. As such, we downgrade our rating to Sell with a target price of $5.
Related Stories
The above story is the opinion of the author only and it does not reflect
iStockAnalyst opinion. Further, the author is not personally advising you
regarding the suitability of the story for your investment needs. In no event
iStockAnalyst will be liable for any loss or damage including without
limitation, indirect or consequential loss or damage, or any loss or damage
whatsoever arising from or arising out of, or in connection with the use of this
information. Please consult your investment advisor before making any investment
decision.
